Lilly’s atopic dermatitis drug hits endpoints
admin 27th August 2019 Uncategorised 0Both the 4mg and 2mg dosages met the trials’ primary endpoint in BREEZE-AD1 and BREEZE-AD2.
More: Lilly’s atopic dermatitis drug hits endpoints
Source: News
Both the 4mg and 2mg dosages met the trials’ primary endpoint in BREEZE-AD1 and BREEZE-AD2.
More: Lilly’s atopic dermatitis drug hits endpoints
Source: News
Data favor Merck, Eisai’s Keytruda-Lenvima as the winner in kidney cancer, but window still open for Bristol Myers: analyst
Data favor Merck, Eisai’s Keytruda-Lenvima as the winner in kidney
FDA could reject AstraZeneca’s COVID vaccine on efficacy and manufacturing shortfalls: analyst
FDA could reject AstraZeneca’s COVID vaccine on efficacy and manufa
Pfizer, Moderna pledge more mRNA vaccine doses to Europe after AZ supply concerns
Pfizer, Moderna pledge more mRNA vaccine doses to Europe after AZ sup
M | T | W | T | F | S | S |
---|---|---|---|---|---|---|
1 | 2 | 3 | 4 | 5 | 6 | 7 |
8 | 9 | 10 | 11 | 12 | 13 | 14 |
15 | 16 | 17 | 18 | 19 | 20 | 21 |
22 | 23 | 24 | 25 | 26 | 27 | 28 |
29 | 30 | 31 |
© 1994 - 2021 B.M. Pharmaceuticals